Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NYSE:ELMD NYSE:INFU NASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$8.70-0.3%$7.60$4.30▼$18.55$227.37M1.26299,560 shs2,701 shsELMDElectromed$24.84+0.3%$22.26$17.73▼$35.56$208.27M0.4783,102 shs1,266 shsINFUInfuSystem$10.500.0%$9.43$4.61▼$11.04$214.37M1.79185,225 shs17,175 shsPYPDPolyPid$3.48-1.8%$3.42$2.30▼$3.93$55.24M1.5186,921 shs6,269 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx+0.23%+12.21%+11.64%+29.33%-0.57%ELMDElectromed-1.20%+0.94%+1.23%+23.73%+14.36%INFUInfuSystem+1.35%0.00%+3.35%+71.29%+55.56%PYPDPolyPid+1.14%+6.31%+2.61%+3.21%-1.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$8.70-0.3%$7.60$4.30▼$18.55$227.37M1.26299,560 shs2,701 shsELMDElectromed$24.84+0.3%$22.26$17.73▼$35.56$208.27M0.4783,102 shs1,266 shsINFUInfuSystem$10.500.0%$9.43$4.61▼$11.04$214.37M1.79185,225 shs17,175 shsPYPDPolyPid$3.48-1.8%$3.42$2.30▼$3.93$55.24M1.5186,921 shs6,269 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx+0.23%+12.21%+11.64%+29.33%-0.57%ELMDElectromed-1.20%+0.94%+1.23%+23.73%+14.36%INFUInfuSystem+1.35%0.00%+3.35%+71.29%+55.56%PYPDPolyPid+1.14%+6.31%+2.61%+3.21%-1.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.63Moderate Buy$14.0060.92% UpsideELMDElectromed 3.50Strong Buy$36.2545.93% UpsideINFUInfuSystem 3.75Strong Buy$13.5028.63% UpsidePYPDPolyPid 2.86Moderate Buy$12.40256.83% UpsideCurrent Analyst Ratings BreakdownLatest PYPD, INFU, ELMD, and CVRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025CVRXCVRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PYPDPolyPidWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025ELMDElectromedZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/22/2025INFUInfuSystemLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.008/27/2025ELMDElectromedLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.008/27/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.008/27/2025ELMDElectromedLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/14/2025PYPDPolyPidCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.00 ➝ $13.008/14/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/13/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/5/2025CVRXCVRxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$11.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$51.29M4.44N/AN/A$2.93 per share2.97ELMDElectromed$64M3.25$0.60 per share41.36$5.10 per share4.87INFUInfuSystem$139.89M1.53$0.82 per share12.79$2.47 per share4.25PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$59.97M-$2.10N/AN/AN/A-95.61%-79.31%-40.96%11/4/2025 (Estimated)ELMDElectromed$5.15M$0.8433.15∞N/A11.34%15.71%13.37%N/AINFUInfuSystem$870K$0.23174.9533.85N/A1.12%2.78%1.41%N/APYPDPolyPid-$29.02M-$3.83N/A∞N/AN/A-453.95%-138.92%11/12/2025 (Estimated)Latest PYPD, INFU, ELMD, and CVRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025CVRXCVRx-$0.50N/AN/AN/A$14.16 millionN/A8/13/2025Q2 2025PYPDPolyPid-$0.53-$0.78-$0.25-$0.78N/AN/A8/4/2025Q2 2025CVRXCVRx-$0.52-$0.57-$0.05-$0.57$13.22 million$13.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx0.8511.9910.78ELMDElectromedN/A5.104.74INFUInfuSystem0.501.981.59PYPDPolyPidN/A2.282.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%ELMDElectromed40.82%INFUInfuSystem71.13%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipCVRXCVRx18.90%ELMDElectromed14.00%INFUInfuSystem11.40%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.15 million21.21 millionOptionableELMDElectromed1608.38 million7.36 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionablePYPDPolyPid8015.90 million11.97 millionNo DataPYPD, INFU, ELMD, and CVRX HeadlinesRecent News About These CompaniesPolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical CongressSeptember 30, 2025 | quiverquant.comQPolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical CongressSeptember 30, 2025 | globenewswire.comPolyPid (NASDAQ:PYPD) Raised to "Hold" at Wall Street ZenSeptember 28, 2025 | americanbankingnews.comPolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street ZenSeptember 27, 2025 | marketbeat.comPolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by BrokeragesSeptember 25, 2025 | marketbeat.comPolyPid (NASDAQ:PYPD) Stock Price Up 2.9% - Time to Buy?September 23, 2025 | marketbeat.comRoth MKM Sticks to Their Buy Rating for PolyPid (PYPD)September 20, 2025 | theglobeandmail.comShort Interest in PolyPid Ltd. (NASDAQ:PYPD) Decreases By 26.6%September 18, 2025 | marketbeat.comPolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities ConferenceSeptember 17, 2025 | globenewswire.comPolyPid Completes Key GMP Inspection for D-PLEX100 Manufacturing ReadinessSeptember 16, 2025 | msn.comPolyPid completes Israeli Ministry of Health GMP inspectionSeptember 16, 2025 | msn.comPolyPid Ltd. Completes Successful GMP Inspection by Israeli Ministry of Health, Preparing for NDA Submission of D-PLEX₁₀₀September 16, 2025 | quiverquant.comQPolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀September 16, 2025 | globenewswire.comPolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 3, 2025 | globenewswire.comPolyPid Ltd. Earnings Call: Positive Trials and Financial StrengthSeptember 2, 2025 | theglobeandmail.comPolyPid Ltd. to Present at Israel Controlled Release Society Conference on Advances in Drug Delivery TechnologySeptember 2, 2025 | quiverquant.comQPolyPid to Present at the 14th Meeting of the Israel Controlled Release Society ConferenceSeptember 2, 2025 | globenewswire.comPolyPid price target raised to $10 from $9 at Roth CapitalAugust 14, 2025 | msn.comPolyPid Releases Mid-2025 Financial UpdateAugust 14, 2025 | theglobeandmail.comPolyPid Reports Strong Phase 3 Results and Financial UpdateAugust 14, 2025 | msn.comPolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYPD, INFU, ELMD, and CVRX Company DescriptionsCVRx NASDAQ:CVRX$8.70 -0.03 (-0.34%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Electromed NYSE:ELMD$24.84 +0.07 (+0.29%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.InfuSystem NYSE:INFU$10.50 -0.01 (-0.05%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.PolyPid NASDAQ:PYPD$3.48 -0.07 (-1.84%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
